GC Partners Increases Stake in SANIGEN to 48% via Discounted Third-Party Allotment, Raising Dilution Concerns for Minority Shareholders

GC Partners reported holding 6,672,848 shares of SANIGEN as of July 10, 2026, increasing its stake from 45.50% to 48.00%.
The change resulted from a third-party allotment capital increase on July 6, 2026, where GC Partners acquired 637,845 common shares at 1,411 KRW per share, a 31% discount to the current market price of 2,050 KRW.
This issuance dilutes existing minority shareholders by approximately 4.8% based on pre-issuance shares, raising about 900 million KRW or 3.3% of market cap. The purpose of the capital increase is undisclosed, adding uncertainty.
GC Partners is a domestic corporation with no reported regulatory issues, but the discounted issuance and dilution may pressure the stock price in the near term.
[AI Summary]The major shareholder's participation in a discounted capital increase signals insider confidence but imposes dilution on other shareholders. The undisclosed use of proceeds and the discount rate suggest potential short-term downside risk.